heavy chain of the IgM-RF Sie) has been described previously (7) . It is composed of GluTrp-Lys-Gly-Gln-VaI-Asn-Vai-Asn-Pro-Phe-Asp-Tyr-Gly-Gly-Cys.
Immunization of Animals. The synthetic peptide PGL 1 was conjugated via its terminal cysteine to keyhold limpet haemocyanin (KLH) with M-maleimidobenzoyl N-hydroxysuccinamide ester, as described previously (10) . Each of three rabbits was injected subcutaneously with 5 mg of the conjugate, emulsified in complete Freund's adjuvant (CFA). The rabbits were boosted twice: 1 mg on day 30 and 2 mg on day 120. The rabbits were bled at various times and the anti-GIo antiidiotype activity was monitored by enzymelinked immunosorbent assay (ELISA).
Purification of Proteins. Plasma or purified proteins from patients with monoclonal
IgM cryoglobulins were kindly provided by Drs. J. D. Capra, G. Abraham, F. Goni, B. Fragione, J. Johnson, and H. Metzger. The IgM cryoglobulins were purified as described previously (8) . Pooled human IgG was prepared from Cohn fraction II (Sigma Chemical Co., St. Louis, MO) by DEAE cellulose chromatography in 0.01 M sodium phosphate, pH 8.0.
ELISA. This was done exactly as described previously (7, 8) . Briefly, antigens (2 #g/ ml) in 0.1 M borate, 0.2 M NaC1, pH 8.2 (BBS) were used to coat microtiter plates (3590; Costar, Data Packaging, Cambridge, MA) at 100 #l/well. After blocking with 1% bovine serum albumin (BSA), 100-#1 samples diluted in BBS containing 0.5% BSA were distributed to duplicate wells. The plates were incubated for 3 h at room temperature, and the bound antibodies were quantified by the binding of human IgG-adsorbed, alkaline phosphatase-labeled goat anti-rabbit IgG (Kirkegaard & Perry Laboratories, Gaithersburg, MD).
Protein Blotting. The reactivity of the anti-PGL1 antibody with immunogiobulin molecules was analyzed by the immunoblot method (11, 12) with some modifications. Briefly, ~ 10 #g of individual monoclonal IgM-RF proteins (5, 7, 13) or pooled human IgG, in 20 #i sample buffer supplemented with 0.01% 2-mercaptoethanol, was loaded onto each slot of a 10% polyacrylamide slab gel containing 0.1% sodium dodecyl sulfate (14) . After electrophoresis (2.5 h at 30 mA), the proteins in the gel were transferred electrophoreticaily to nitrocellulose paper (2 h at 70 V). Protein-binding sites on the paper were quenched with 0.01 M phosphate-buffered saline (PBS), pH 7.2, containing 5% BSA, for 1 h at room temperature. Subsequently, the paper was overlaid with anti-PGL1 antiserum for 1 h. After washing with BBS, the paper was developed with ~5I-labeled protein A (1 mCi/mg, 2 × 10 s cpm/mi) for another hour. After extensive washing with BBS, the paper was dried and finally exposed to Kodak XAR-5 film overnight at -70°C.
Affinity Chromatography. The globulin fraction of the rabbit antiserum, prepared by precipitation with a 33% saturated ammonium sulfate, was adsorbed sequentially with a BSA-Sepharose 4B column (13.4 mg/ml × 1.5 ml) and a rabbit IgG-Sepharose 4B column (8.3 mg/ml × 1 mi) to remove nonspecific binding material and any possible rabbit RF activity. The adsorbed antibody was then circulated over a human IgGSepharose 4B column (9.5 mg/mi × 2 ml). After removal of nonbound material with BBS, the bound antibody was eluted with 0.1 M glycine-hydrochloric acid, pH 2.5, and then was immediately neutralized with Tris base (Sigma Chemical Co.).
Results
Induction of Anti-RF Antibody With the PGL1 Peptide. After receiving two subcutaneous injections of the PGL1 peptide conjugated to KLH, the rabbits were bled, and their sera were analyzed for antipeptide antibody activity by ELISA. All three immunized rabbits produced anti-PGL 1 antibody. Two of the antisera reacted significantly with the corresponding intact IgM-RF Glo (Table  1) .
Since IgM-RF Glo reacted with rabbit IgG, an immunoblot assay was used to demonstrate the de facto antiidiotype activity of the anti-PGL1 antiserum (7) . IgM-RF GIo and the control, pooled human IgG (Cohn fraction II), were Immune 2 ----449
The rabbit was immunized with PGLI-KLH in CFA on days 0, 30, and 120, and was bled on day 70 (immune 1) and 135 (immune 2). The antisera were assayed at 1:100 dilution.
fractionated by electrophoresis under reducing conditions, and then transferred onto nitrocellulose paper. After incubation with the antipeptide antibody and final development with ~25I-labeled protein A, autoradiographs were prepared. Fig. 1 shows that the anti-PGL1 antiserum reacts with the kappa light chain of Glo, but not with the heavy chain of Glo, nor with the light chains of pooled human IgG. Thus, the anti-PGL1 displays antiidiotypic activity. Subsequently, the specificity of the anti-PGL1 antiserum against a panel of human IgM-RF was examined by the immunoblot method. Fig. 2 shows that anti-PGL1 antibody reacts well with IgM-RF proteins Gar, Glo, Got, and Pal, very weakly with Neu, Pay and Sie (data for Sie not shown), and not at all with IgM-RF Lay. Except for IgM-RF Pal, the amino acid sequences of the first CDR of the kappa chains of these IgM-RF have been reported (9, 13, 15, 16) and are shown in Table II . These results suggest that the majority of the polyclonal anti-PGL 1 antibodies recognize a determinant associated with Val-Ser-Ser-Ser (residues 28-31). However, the anti-PGL1 antibodies also react with IgM-RF Got, which has Arg instead of Ser at position 29. One possible explanation is that the antigenic determinant for the majority of antiidiotype is Ser-Ser-Ser, that a lesser fraction recognizes Ser-Ser-Tyr, and that Val serves to enhance the binding of both antibodies through its hydrophobicity (see Discussion). Since both Ser and Tyr share the same functional hydroxyl group, the Ser-Ser-Tyr-and Ser-SerSer-specific antibodies might be expected to have partial cross-reactivity.
Anti-PGLI Antibody Reacts With Human IgG. The epibody described by Bona et al. (4) was prepared against human IgM-RF Glo, which contain the PGL1 sequence. As shown in Fig. 1 , the PGLl-induced antiidiotype bound to the isolated gamma chains of human IgG. To assess the structural basis for this crossreaction, two types of experiments were performed. First, the antibody-binding activity to the gamma chains was inhibited partially by the free PGL1 peptide in solution (Fig. 1) . Under the same conditions, an unrelated peptide, PSH3 (7), did not detectably inhibit the reaction (data not shown). However, it should be noted that the peptide inhibition of antibody binding to IgG gamma chain was not as significant as to GIo light chain, reaching a maximum of -70% (as FIGURE 1. The epibody activity of the anti-PGL1 antiserum. 10 tzg of each sample was loaded into each slot. The polypeptides were transferred after sodium dodecyl sulfatepolyacrylamide gel electrophoresis, and were incubated with the indicated antibodies (anti-PGL1 at 1:20 dilution, anti-human lg at 5 #g/ml) and inhibitor PGL1 (50 ~g/ml).
suggested by the intensity of autoradiographs). This suggests that some antigamma antibodies might have been induced nonspecifically or indirectly.
Second, the PGLl-induced epibodies were enriched by affinity chromatography on a human IgG column. As shown in Fig. 3 , the eluate from the human IgG column reacted with both the Glo light chain and IgG gamma chains, but not with IgG light chains. However, the binding to Glo light chain, but not to IgG gamma chain, was completely inhibited by the PGL1 peptide. Altogether, these results suggest that a portion of PGLl-induced antiidiotype reacted with intact IgG molecules, and that anti-PGL1 antiserum contains both epibody and anti-gamma antibody that was indirectly induced. Discussion An antiidiotype with "epibody" properties against the human monoclonal IgM-RF Glo was generated by immunization of a rabbit with a synthetic peptide (PGL1), corresponding to the first CDR of the Glo kappa light chain. The antibody reacted specifically with both the PGL1 and the intact IgM-RF Glo. Residue number according to Kabat et al. (21) . * Amino acid sequences were reported by Capra and Kehoe (9) . at Amino acid sequences were reported by Ledford et al. (13) . 0 Amino acid sequences were reported by Klapper and Capra (15) . I Amino acid sequences were reported by Andrews and Capra (16) .
W h e n analyzed by the i m m u n o b l o t m e t h o d , the anti-PGL1 a n t i b o d y r e c o g n i z e d the isolated kappa chains o f the I g M -R F paraproteins GIo, Gar, Got, a n d Pal, b u t not the kappa chains o f I g M -R F Lay. T h e anti-PGL1 a n t i b o d y did not bind detectably to the heavy chains o f any IgM-RF. T h e binding o f the antiserum to the Glo kappa chain was completely inhibited by the free P G L 1 peptide, but n o t by a control peptide (PSH3). T h u s , the synthetic P G L 1 peptide i n d u c e d an antiidiotype against a cross-reactive idiotype associated with the kappa chains o f several human IgM-RF autoantibodies. The molecular basis of this cross-reactive idiotype is defined by the PGL1 amino acid sequence.
In our initial observations of the anti-PGL 1 antibody, we were surprised and disappointed by its binding with the gamma chain of the pooled human IgG. However, the epibody described by Bona et al. (4) prompted us to study the exact specificities of this peculiar antiserum.
The epibody was defined (4) as an antiidiotype that reacted with the antigen of the idiotype-bearing antibody. Experiments were done to demonstrate that a portion of the PGL 1-induced 'polycional' antiidiotype did react additionally with human IgG, as a regular antibody reacts with its antigen. Fig. 1 shows that the binding of PGLl-induced antiidiotype with IgG gamma chain was partially inhibited by PGL 1, suggesting that there are at least two sets of anti-gamma components in the polyclonal antiserum, and that only one set recognizes the PGL 1-associated epitope on the IgG gamma chain. Fig. 3 shows that both sets of anti-gamma antibodies in the serum can be adsorbed by, and eluted from, a human IgG column, demonstrating that they react with intact IgG molecules. In addition, the anti-PGL1 antibodies, previously adsorbed with a human IgG column, still reacted with the Glo light chains (data not shown). In contrast, the human IgG column eluate of anti-PGL1 antisera that was subsequently passed through a PGL1 column reacted only with IgG, and not Glo (data not shown). By pooling these data, the anti-PGL1 antibodies can be classified as follows (Table Ill) : (a) conventional antiidiotype that reacts with GIo light chain only, and whose antibody reactivity is completely inhibited by PGL1; (b) epibody that reacts with both Gio light chain and IgG, and whose antibody reactivity is inhibitable by PGL1; and (c) anti-IgG antibody that reacts with IgG only, and whose binding is not inhibitable by PGL1.
It should be pointed out that the epibody constitutes only a very small portion of the overall anti-PGL1 antibodies, that its binding to the separated Glo light chain and IgG gamma chain is of low affinity, and that the binding to intact Glo and intact IgG is of even lower affinity. The anti-IgG component was induced indirectly, possibly through the immune network or other unknown mechanisms.
Other than the original description by Bona et al. (4) , the existence of epibodies has not been confirmed, so their biological significance could not be investigated. The current paper confirms independently the existence of epibodies. Moreover, it is likely that the structural basis of the epibody described here is the Ser-SerSer sequence shared by the reactive IgM-RF (Glo and Gar) and human IgG molecules [residue 195-197 , number according to Kabat et al. (21) ]. This is based on the following: (a) Anti-PGL1 recognizes mainly a determinant consisting of VaI-Ser-Ser-Ser (Fig. 2) ; (b) antiidiotypes, induced by a similar peptide PSL 1 (which corresponds to the first CDR of Sie light chain and is identical to PGL 1 except for having Asn instead of Ser at position 9), did not react with human IgG (unpublished data); (c) anti-PGL1 reacted with the F(ab')2, but not Fc, of the human. IgG (data not shown); (d) three of six gamma chains with known sequences (Eu, Nie, and IgG G4) have Ser-Ser-Ser at position 195-197, while neither one of two p chains (Gal and Ou) have Ser-Ser-Ser sequence.
Numerous investigations using dextran and homopolymers of amino acids have concluded that the antibody-combining site can accommodate a hexasaccharide or tetrapeptide (22) . In addition, analysis of the antigenic determinant size of the protein antigens revealed that a determinant consisted of a pentapeptide or a tetrapeptide (reviewed in 23). Moreover, in the case of C-terminal pentapeptide of tobacco masaic (TMV) virus, Leu-Asp-Ala-Thr-Arg, the LeuAsp could be replaced by N-octanoyl (24) . This suggested that the anti-TMV antibodies recognized specifically the tripeptide Ala-Thr-Arg, while the Leu-Asp enhanced the antibody binding by providing hydrophobicity. Thus, the loss of idiotype in the RF Pay can be explained by the decreased hydrophobicity, due to the Val ~ Lys substitution at position 28. Similarly, it is interesting to note that IgG has Vai-Pro at the N-terminal to Ser-Ser-Ser (21).
Summary
Recently, an antiidiotype to human monocional IgM anti-IgG autoantibodies (rheumatoid factors) was found to react also with human IgG. This peculiar antiidiotype was called an 'epibody'. We describe the induction of a similar epibody by immunization with a synthetic peptide (corresponding to one hypervariable region of the IgM-RF Glo). The results confirm the existence of epibodies, and provide the possible molecular basis of the epibody phenomenon.
